These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 17689357)

  • 1. Merseyside, the first harm reduction conferences, and the early history of harm reduction.
    O'Hare P
    Int J Drug Policy; 2007 Mar; 18(2):141-4. PubMed ID: 17689357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advocacy for harm reduction in China: a new era dawns.
    Reid G; Aitken C
    Int J Drug Policy; 2009 Jul; 20(4):365-70. PubMed ID: 19097773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of community-based nurses in harm reduction for HIV prevention: a South East and South Asia case study.
    Limbu B
    Int J Drug Policy; 2008 Jun; 19(3):211-3. PubMed ID: 18440796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Young people and drugs: next generation of harm reduction.
    Merkinaite S; Grund JP; Frimpong A
    Int J Drug Policy; 2010 Mar; 21(2):112-4. PubMed ID: 20036526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Learning from HIV epidemics among injecting drug users.
    Jarlais DC
    Int J Drug Policy; 2010 Mar; 21(2):97-9. PubMed ID: 20018500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public Health and the origins of the Mersey Model of Harm Reduction.
    Ashton JR; Seymour H
    Int J Drug Policy; 2010 Mar; 21(2):94-6. PubMed ID: 20163946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coverage to curb the emerging HIV epidemic among injecting drug users in Pakistan: delivering prevention services where most needed.
    Emmanuel F; Fatima M
    Int J Drug Policy; 2008 Apr; 19 Suppl 1():S59-64. PubMed ID: 18281206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Legal harm reduction among intravenous drug users.
    Kongsakon R; Pocham N
    J Med Assoc Thai; 2006 Sep; 89(9):1545-50. PubMed ID: 17100399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users.
    Van Den Berg C; Smit C; Van Brussel G; Coutinho R; Prins M;
    Addiction; 2007 Sep; 102(9):1454-62. PubMed ID: 17697278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coexisting or conjoined: the growth of the international drug users' movement through participation with International Harm Reduction Association Conferences.
    Byrne J; Albert ER
    Int J Drug Policy; 2010 Mar; 21(2):110-1. PubMed ID: 19942422
    [No Abstract]   [Full Text] [Related]  

  • 11. 'Social evils' and harm reduction: the evolving policy environment for human immunodeficiency virus prevention among injection drug users in China and Vietnam.
    Hammett TM; Wu Z; Duc TT; Stephens D; Sullivan S; Liu W; Chen Y; Ngu D; Des Jarlais DC
    Addiction; 2008 Jan; 103(1):137-45. PubMed ID: 18028519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Theorizing "Big Events" as a potential risk environment for drug use, drug-related harm and HIV epidemic outbreaks.
    Friedman SR; Rossi D; Braine N
    Int J Drug Policy; 2009 May; 20(3):283-91. PubMed ID: 19101131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the efficacy and effectiveness of harm reduction strategies for alcohol, tobacco and illicit drugs.
    Ritter A; Cameron J
    Drug Alcohol Rev; 2006 Nov; 25(6):611-24. PubMed ID: 17132577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid scale up of harm reduction in China.
    Sullivan SG; Wu Z
    Int J Drug Policy; 2007 Mar; 18(2):118-28. PubMed ID: 17689354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switzerland, HIV and the power of pragmatism: lessons for drug policy development.
    Csete J; Grob PJ
    Int J Drug Policy; 2012 Jan; 23(1):82-6. PubMed ID: 21852097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal uptake of sterile drug preparation equipment in a predominantly cocaine injecting population: implications for HIV and hepatitis C prevention.
    Morissette C; Cox J; De P; Tremblay C; Roy E; Allard R; Stephenson R; Graves L
    Int J Drug Policy; 2007 May; 18(3):204-12. PubMed ID: 17689367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Injecting risk behaviour and related harm among men who use performance- and image-enhancing drugs.
    Larance B; Degenhardt L; Copeland J; Dillon P
    Drug Alcohol Rev; 2008 Nov; 27(6):679-86. PubMed ID: 18825549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The organization of a community: community-based prevention of injecting drug use-related health problems.
    Carruthers S
    Subst Use Misuse; 2007; 42(12-13):1971-7. PubMed ID: 18075921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
    Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
    Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reduction.
    Hallinan R; Byrne A; Dore GJ
    Drug Alcohol Rev; 2007 Jul; 26(4):437-43. PubMed ID: 17564882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.